title: Supplemental iron via dialysate: a novel mode of delivery for hemodialysis patients.
abstract: Gupta et al. describe a novel strategy for iron administration to hemodialysis patients, giving ferric pyrophosphate citrate via the dialysate. PRIME, a randomized controlled study comparing this technology against placebo, shows a 35% reduction in prescribed erythropoiesis-stimulating agent dose. The findings may be explained in part by a restrictive protocol for intravenous iron administration in the placebo group, producing lower ferritin levels. There were no obvious safety concerns. The general applicability of this technology, and its cost-effectiveness, are unclear at the present time.
authors.affiliation: Department of Renal Medicine, King's College Hospital, London, UK.
authors.forename: Iain C
authors.initials: IC
authors.lastname: Macdougall
mesh_terms: D018798:Anemia, Iron-Deficiency / Q000188:drug therapy; D015314:Dialysis Solutions / Q000627:therapeutic use; D005290:Ferric Compounds / Q000627:therapeutic use*; D006801:Humans; D007501:Iron / Q000008:administration & dosage*; D006435:Renal Dialysis
chemical_list: D015314:Dialysis Solutions; D005290:Ferric Compounds; D007501:Iron